Rossari Biotech Reports Q1 Results Amid Group Restructuring and ESOP Allotment

Rossari Biotech Reports Q1 Results Amid Group Restructuring and ESOP Allotment​

Rossari Biotech Limited, during its Board of Directors meeting on July 18, 2026, announced key outcomes including unaudited financial results for the quarter ending June 30, 2026, a significant corporate restructuring move, and an update on its employee stock option plan.

The company's board reviewed and approved the consolidated and standalone unaudited financial results for the recently concluded quarter. These results were subjected to Limited Review by the Statutory Auditors of the Company.

Financial Performance Overview (Q1 FY 2026)​

Consolidated Results:
The consolidated statements showed strong performance for the group during the quarter ended June 30, 2026. The Group reported Total Income of Rs. 7,003.87 million. Revenue from operations stood at Rs. 6,972.00 million.

Key financial metrics in consolidated results include:

• Total Expenses: Rs. 6,531.72 million
• Profit before Tax: Rs. 476.72 million
• Total Tax Expense: Rs. 125.77 million
• Profit after Tax: Rs. 350.95 million

Standalone Results:
The standalone financial results reflected the company's operational strength, with Total Income reaching Rs. 4,844.63 million for the quarter ending June 30, 2026. Revenue from operations was reported at Rs. 4,822.75 million.

Standalone metrics include:

• Total Expenses: Rs. 4,380.42 million
• Profit before Tax: Rs. 464.21 million
• Total Tax Expense: Rs. 121.55 million
• Profit after Tax: Rs. 342.66 million

Corporate Restructuring and Shareholding Transfer​

The Board of Directors approved a strategic internal group restructuring move involving Rossari International Limited Company (RILC), a wholly owned subsidiary, and Rossari (Singapore) Pte. Ltd. (Rossari Singapore), which is also a wholly owned subsidiary.

Under the approved transaction, the company will transfer its 100% shareholding in RILC to Rossari Singapore. The restructuring aims to simplify overseas regulatory reporting by establishing a common holding platform through a single existing overseas investment subsidiary.

The transition means that RILC will become a wholly owned subsidiary of Rossari Singapore and a step-down wholly owned subsidiary of the parent company. The transaction is contingent upon the execution of a Share Purchase Agreement and receiving requisite approvals from authorities in the Kingdom of Saudi Arabia.

Employee Stock Option Plan (ESOP) Updates​

The Board also took key actions regarding the Rossari Employee Stock Option Plan - 2019.

Option Grant:
A grant of 4,000 Stock Options under ESOP 2019 was approved. The exercise price for these options is set at Rs. 531 per option. Employees holding the options will have a vesting schedule spread across four years, with options vesting at the end of each year (20%, 20%, 20%, and 40% respectively).

Share Allotment:
The Board approved the allotment of 2,500 Equity Shares of Rs. 2/- each to grantees upon exercising options granted under ESOP 2019. This successful allotment increased the issued and paid-up equity share capital of the company to Rs. 11,07,88,232, corresponding to a total of 55,394,116 Equity Shares.

Subsidiary Details​

Rossari Biotech Limited's consolidated results include financial information from various entities across its global operations. These entities include foreign subsidiaries such as Rossari Global FZCO and Rossari Bangladesh Limited (under liquidation), along with Indian subsidiaries like Buzil Rossari Private Limited and Rossari Consumer Products Private Limited, an associate company, and a joint venture company.

ROSSARI Stock Price Movement​

Shares of Rossari Biotech Limited on Friday slipped 1.30%, settling at ₹531.45 after the stock fell by ₹7.05 from its previous closing level. The equity traded within a narrow band during the session, hitting a low of ₹524.60 amidst 72,267 shares being transacted.